Improved outcomes of all-trans-retinoic acid and arsenic trioxide plus idarubicin as a frontline treatment in adult patients with acute promyelocytic leukemia

We analyzed the outcomes of all-trans-retinoic acid (ATRA) and IV arsenic trioxide (ATO) plus idarubicin (IDA) as a frontline induction therapy in 118 acute promyelocytic leukemia (APL) patients with high risk (HR) and standard risk (SR) from January 2008 to December 2017. The medical records of 118 APL patients (HR, n=45; SR, n=73) who received the frontline triple combination regimen at Henan Provincial People ’s Hospital and Tongji Hospital were retrospectively reviewed. Consolidation therapy comprised 6 cycles of ATO and ATRA plus IDA, and IDA was administered in 1∼4 cycles of consolidation therapy based on the comparable clinical efficacy compared with 6 cycles and fewer side effects to myocardium without subsequent maintenance therapy.

Source: Clinical Lymphoma, Myeloma and Leukemia - October 13, 2019 Category: Hematology Authors: Shiwei Yang, Rongjun Ma, Xiaoli Yuan, Li Jiang, Jie Shi, Jing Yang, Pingchong Lei, Yuzhu Zang, Xiangli Chen, Yin Zhang, Zhongwen Liu, Jianmin Guo, Lin Zhang, Xiaojian Zhu, Zunmin Zhu Tags: Original Study Source Type: research